Minjuvi Gains Accelerated Funding in Ontario for Relapsed/Refractory Follicular Lymphoma
Incyte announced that Minjuvi (tafasitamab), in combination with R² (lenalidomide and rituximab), is now funded in Ontario through the Funding Accelerated for Specific Treatments (FAST) Program for eligible patients with relapsed or refractory follicular lymphoma. The pathway enables earlier access while formal reimbursement processes continue, providing another targeted treatment option for a disease where relapse is common and treatment options can become more limited over time. Ontario is the first province to fund Minjuvi for R/R FL, marking a milestone in expanding access to innovative cancer therapies across Canada.
Anzupgo Moves Closer to Public Reimbursement in Canada
LEO Pharma Canada and pCPA have successfully concluded negotiations for Anzupgo (delgocitinib cream), signing a Letter of Intent that advances public reimbursement for eligible adults with moderate to severe chronic hand eczema. Anzupgo is the first topical treatment specifically indicated for adults with moderate to severe CHE inadequately controlled with, or unsuitable for, topical corticosteroids. Following a positive CDA-AMC recommendation, LEO Pharma will work with public drug plans and INESSS on listing decisions, bringing the treatment closer to broader access across Canada.
Siliq Gains Alberta Public Drug Plan Coverage
Bausch Health Canada announced that Siliq (brodalumab) is now reimbursed under Alberta’s public drug plan for eligible adults with moderate to severe plaque psoriasis who meet applicable criteria. Indicated for patients who are candidates for systemic therapy or phototherapy, Siliq has been available in Canada since 2018. Alberta’s decision expands its public coverage across Canada, leaving British Columbia as the only province without public drug plan coverage and providing eligible patients with another treatment option for managing the chronic condition.
